Search
The FDA and Novo Nordisk are warning the public about counterfeit Ozempic injections circulating in the U.S. drug supply chain. The falsified products, labeled with lot number PAR0362 and serial numbers beginning with 51746517, were seized by the FDA on April 9, 2025. Their contents and safety are unverified and pose serious health risks.
Read More
Prescription Drug Affordability Board Activity through March 31, 2025 Activities Summary Colorado: Colorado’s PDAB cancelled its March meetings. Maryland: Maryland’s PDAB met on March 24, 2025 to begin a cost review of Farxiga and review feedback about updates to PDAB regulations. Oregon: Board members met on March 19, 2025, where they elected a subset of drugs for affordability reviews. 31…
Read More
PSM is seeking input on developing a set of best practices to reduce sales of counterfeit and diverted medicines on online pharmacy-to-pharmacy marketplaces.
Read More
The FDA announced that it had seized counterfeit Ozempic injections on April 9. PSM testified at a congressional hearing.
Read More
A study examined the 130 enforcement actions undertaken by the U.S. Food and Drug Administration’s Office of Criminal Investigations from 2016 through 2021.
Read More
The state of Colorado submitted a revised application to the U.S. Food and Drug Administration to operation a Canadian drug importation plan in March. This blog post examines how the state’s application has changed over the years.
Read MorePSM has sent open records requests to several towns and schools with self-funded health plans about their relationships with Alternative Funding Vendors.
Read More
A March 12, 2025 memo said the state had paid more than $150,000 defending itself in a lawsuit Amgen had filed over plans to set an upper payment limit on its rheumatoid arthritis treatment, Enbrel.
Read More
Senator Jim Banks asked pointed questions about how FDA will stem the tide of semaglutide and tirzepatide coming from unknown facilities.
Read More
Compounded versions of GLP-1 injectable treatments for diabetes and obesity have surged in popularity despite a lack the safety and efficacy assurances. The FDA has warned that these knockoff versions sometimes contain illicit semaglutide or tirzepatide-the active pharmaceutical ingredients (APIs) in weight loss drugs. Working with George Karavetsos, former director of FDA’s Office of Criminal Investigations and a federal prosecutor,…
Read More